American Gene Technologies®

In The News

Try these: Jeff GalvinHIVAmerican Gene TechnologiesPhenylketonuria

As seen in the Parenteral Drug Association (PDA) magazine Letter, AGT CEO Jeff Galvin talks about how we can reprogram the human computer

Parenteral Drug Association: “Can We Reprogram The Human Computer?”

Dec 5, 2019

Published by: Parenteral Drug Association (PDA), In: Volume LV, Issue 9  |  Written by: Rebecca Stauffer Download The Full PDF What if developers of cell and gene therapies treated their products like software releases? What if the human body could be manipulated like a highly complex computer?…

Read More
ABC4 reports on AGT's submission of AGT103-T to the FDA

ABC4: Maryland company believes it has cure for HIV/AIDS

Nov 8, 2019

Published by: abc4.com  Written by: Janay Parrott ROCKVILLE, Md. (WDVM) – Wednesday night was an exciting one for investors and employees at American Gene Technologies. After years in the making, they submitted a nearly 1,000-page document to FDA. And within its pages just may lie…

Read More
BiotechPrimer explores AGT's potential HIV cure using gene therapy

Biotech Primer: Gene Therapy Targets AIDS

Sep 12, 2019

Published by: BiotechPrimer  Written by: Emily Burke, PhD For many years, a diagnosis of acquired immunodeficiency syndrome (AIDS) was a death sentence. It seemed unthinkable in the 1980s, but the medical community now largely treats the disease as a chronic illness. This profound shift arose through…

Read More
OneZero explores AGT's potential gene therapy cure for HIV

One Zero: “The Gene Fix That Could Cure HIV”

Sep 6, 2019

Published by:  One Zero  Written by:  Emily Mullin Antiretroviral drugs make HIV manageable, but gene therapies could eliminate the virus altogether — provided the treatments can be made safe and economical In the mid-1990s, scientists made a curious but remarkable discovery: A man named Stephen Crohn seemed…

Read More
Montgomery Magazine profiles Jeff Galvin and American Gene Technologies and explores its potential HIV cure

Montgomery Magazine: “Jeffrey Galvin’s BioTech Firm May Be on The Verge of Curing HIV/AIDS”

Aug 19, 2019

Written by: Jeff Thoreson | Photograph by: Kevin Allen A 3D RENDERING OF HIV VIRUS IN BLOOD STREAM Jeffrey Galvin has been a computer nerd since the seventh grade. Way back in the 1970s era of mainframes, he became interested not so much in programming…

Read More
Executive Leadership Radio Show on WFED 1500AM Interviewed CEO Jeff Galvin

Executive Leadership Radio Show on WFED 1500AM Interviewed CEO Jeff Galvin

Jul 22, 2019

Aired On: WFED Federal News Radio 1500 AM On July 7, 2019, Executive Leadership Radio hosts Herb Cohen and Jeffrey E. Mack interviewed CEO Jeff Galvin. This interview gets to the heart of Galvin’s life story, his parents, his experience growing up in Massachusetts, and…

Read More
Chemical & Engineering News features AGT and its mission to develop a gene therapy cure for PKU

C&EN: “How Phenylketonuria, A Once-Neglected Disease, Became A Proving Ground For New Drugs”

Jul 9, 2019

Published by: C&EN on May 12, 2019, In: Volume 97, Issue 27.  Written by: Ryan Cross After decades of yearning for drugs, people with PKU now have 2, and a dozen more are in development. It’s dinnertime on a Wednesday evening in June at the…

Read More
Gene technologies are making strides to cure terminal illnesses

Gene Technologies are Making Strides to Cure Terminal Illnesses

Jul 8, 2019

Published By: What’s Working In Washington | Federal News Network  Written by: Barbour Ulrich Even if you work in the D.C. region, you may not be privy to a world-changing industrial revolution happening right now, in places around the world. To talk about that is…

Read More
Chemical & Engineering News profiles several HIV treatments and cures in development, which includes AGT's AGT103-T

C&EN: “With Several Long-acting HIV Treatments In The Works, The Newest Drugs Emphasize Convenience”

Jun 18, 2019

Published by: C&EN on May 12, 2019, In Volume 97, Issue 19.  Written by: Megha Satyanarayana Lionel Hillard’s boss asked him to come into his office. It was the late 1980s in Dallas. The then 29-year-old was a medical assistant at a busy clinic with…

Read More
Site Selection interviews CEO Jeff Galvin about how Maryland is leading a biotech revolution

Site Selection: “The Future of Healthcare is Here: Maryland Leads a Biotech Revolution”

Jun 17, 2019

Published by: Site Selection, Digital Edition, May 2019 Issue.  Written by: Gary Daughters Jeff Galvin, founder and CEO of Rockville, Maryland’s American Gene Technologies, speaks of cellular gene therapy with the zeal of an evangelist. “I believe we’re on the eve of a gene and…

Read More

Subscribe to News Releases and News Updates

Subscribe to our news release and published article updates to be notified when we release new content!

Follow AGT on Social Media

AGT on Facebook

Jeff Galvin, CEO of American Gene Technologies, shares his journey from Silicon Valley to biotech and the future of gene therapy. Watch the interview on Bio Blast!www.addimmune.com/jeff-galvin-explains-agts-innovative-approach-to-hiv-on-bio-blast/#genetherapy #Biotech #Innovation ... See MoreSee Less
View on Facebook
Tune in to Cell & Gene: The Podcast and hear Addimmune's Dr. Marcus Conant, a pioneer in HIV research, discuss our innovative cell therapy for HIV. He shares his vision for empowering patients and transforming HIV treatment. loom.ly/96TZ0jU#HIV #celltherapy #biotech ... See MoreSee Less
View on Facebook
M&A has been steady in 2024. We count 47 private & public deals to date totaling $53 billion. 15 have been >$1 billion with cancer, rare disease & cell therapies some of the areas of interest. ... See MoreSee Less
View on Facebook
AGT CEO, Jeff Galvin, had a chat with social media influencer and HIV advocate, Raif Derrazi, to discuss the latest updates on our AGT103-T clinical trials. Dive into the conversation as they shed light on the research and what lies ahead in our mission to find a cure for HIV! loom.ly/jAThqIU#HIV #hivcure #HIVresearch #clinicaltrials ... See MoreSee Less
View on Facebook